• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The journal of sexual medicine >Coadministration of Anastrozole Sustains Therapeutic Testosterone Levels in Hypogonadal Men Undergoing Testosterone Pellet Insertion
【24h】

Coadministration of Anastrozole Sustains Therapeutic Testosterone Levels in Hypogonadal Men Undergoing Testosterone Pellet Insertion

机译：阿那曲唑的共同给药可维持性腺功能减退男性进行睾丸药丸插入治疗性睾丸激素水平。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction: Current U.S. Food and Drug Administration-approved therapies for hypogonadism involve testosterone (T) replacement. Testosterone pellets (TP) require a minor office procedure every 3 to 4 months. The need for repeated insertions increases the likelihood of a complication. Anastrozole (AZ) is an aromatase inhibitor that has been used off-label for the treatment of male hypogonadism. AZ increases T levels by lowering serum estradiol (E2) levels and increasing gonadotropin (GTP) levels. Aim: We hypothesized that the concomitant use of AZ with TP insertions would sustain therapeutic T levels and increase the interval between TP insertions. Methods: Men treated with TP for hypogonadism at an academic center were offered AZ (1mg/day) at the time of TP reinsertion as a way of potentially decreasing the frequency of TP insertions. Total T (TT), free T (FT), sex hormone binding globulin, E2, luteinizing hormone (LH), and follicle-stimulating hormone FSH levels were obtained prior to T replacement and at 6 and 15 weeks from TP insertion. Men were re-implanted at 16 weeks if their TT levels were less than 350ng/dL and their symptoms recurred. We retrospectively reviewed our records of men who underwent TP, TP, and AZ from 2011 to 2012. Demographics, TT, FT, LH, FSH, and E2 levels were recorded. Data were analyzed with anova and a Tukey's test. Main Outcome Measure: TT level at 6, 15, or >15 weeks from TP insertion. Results: Thirty-eight men with 65 insertions were analyzed. The TP AZ group had significantly higher TT and FT levels than the TP group at >120 days (P<0.05). The TP group had significantly higher E2 levels at all time points (P<0.01). GTP levels remained stable in the TP AZ group. Average time to reinsertion in TP AZ was 198 days vs. 128 days in the TP group. Conclusion: Men on TP AZ maintain therapeutic T levels longer than men on TP alone and have significantly less GTP suppression.
机译：简介：目前美国食品药品监督管理局批准的性腺功能减退疗法涉及睾丸激素（T）的替代。睾丸激素颗粒（TP）每3到4个月需要做一次小型的办公室程序。重复插入的需要增加了并发症的可能性。阿那曲唑（AZ）是一种芳香化酶抑制剂，已被标签外用于治疗男性性腺功能减退症。 AZ通过降低血清雌二醇（E2）水平和增加促性腺激素（GTP）水平来提高T水平。目的：我们假设将AZ与TP插入同时使用将维持治疗性T水平并增加TP插入之间的间隔。方法：在学术中心接受TP治疗性腺功能低下的男性，在TP再次插入时为其提供AZ（每天1mg），以可能减少TP插入的频率。总T（TT），游离T（FT），性激素结合球蛋白，E2，黄体生成激素（LH）和促卵泡激素FSH水平在置换T之前以及TP插入后第6和15周获得。如果男性的TT水平低于350ng / dL，并且症状再次出现，则在16周时将其重新植入。我们回顾性回顾了2011年至2012年接受TP，TP和AZ的男性的记录。记录了人口统计学，TT，FT，LH，FSH和E2水平。使用方差分析和Tukey检验分析数据。主要观察指标：TP插入后第6、15或15周的TT水平。结果：分析了38例65次插入的男性。在> 120天时，TP AZ组的TT和FT水平显着高于TP组（P <0.05）。 TP组在所有时间点的E2水平均显着升高（P <0.01）。 TP AZ组的GTP水平保持稳定。 TP AZ的平均重新插入时间为198天，而TP组为128天。结论：TP AZ男性比单独使用TP男性维持治疗性T水平更长，并且GTP抑制作用明显降低。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号